Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

New ACAT inhibitors synthesized at Sumitomo

Aug. 31, 1998

Columbia Laboratories develops hormone replacement tablet for men

Aug. 31, 1998

Unimed's Androgel shows promising phase II results

Aug. 31, 1998

Another beta3-adrenergic agent added to the BMS pipeline

Aug. 28, 1998

Ergo Science submits amendment to Ergoset NDA

Aug. 28, 1998

Bristol-Myers Squibb program on beta3-adrenoceptor agonists outlined at ACS

Aug. 27, 1998

Fuji Chemical patents new treatment for kidney disease in diabetic patients

Aug. 27, 1998

Selective alphav/beta3 integrin receptor antagonists from DuPont Pharmaceuticals

Aug. 27, 1998

Further international approvals, product launches announced for Muse

Aug. 27, 1998

Advisory committee recommends European approval for Viagra

Aug. 26, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...